The paper marks the second retraction for one of the co-authors.

The papers were flagged by a method that has now been called into question.

The retracted studies mar hope for the drug’s use in depression.

A growing proportion of researchers has reached such “super principal investigator” status, but the distribution is not even across demographic groups.

The paper used more than two dozen such terms, which have cropped up in thousands of published papers in recent years.

An anonymous tipster has been sifting through the papers of Jia Liu and his team.

The editors intend to start a new nonprofit journal.

Researchers and clinicians were quick to point out the flaws in the study, and a flood of work refuted it.

In this edition of Null and Noteworthy, Spectrum talks with a Nature editor about the journal’s move to publish more null results.

The two journals, although differing in initial support, both realized the need for a publication focused exclusively on the neurodiverse experience.